Literature DB >> 29292214

A mechanistic overview of herbal medicine and botanical compounds to target transcriptional factors in Breast cancer.

Yingke Zhao1, Yue Liu2.   

Abstract

The abnormalities of transcription factors, such as NF-κB, STAT, estrogen receptor, play a critical role in the initiation and progression of breast cancer. Due to the limitation of current treatment, transcription factors could be promising therapeutic targets, which have received close attention. In this review, we introduced herbal medicines, as well as botanical compounds that had been verified with anti-tumor properties via regulating transcription factors. Herbs, compounds, as well as formulae reported with various transcriptional targets, were summarized thoroughly, to provide implication for the future research on basic experiment and clinical application.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Botanical compounds; Breast cancer; Herbal medicine; Transcription factor

Mesh:

Substances:

Year:  2017        PMID: 29292214     DOI: 10.1016/j.phrs.2017.12.027

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  3 in total

1.  Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis.

Authors:  Tong Xu; Yanyu Jiang; Shuying Yuan; Li Zhang; Xihui Chen; Weili Zhao; Lili Cai; Biying Xiao; Lijun Jia
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

2.  Actinidia chinensis Planch Root extract suppresses the growth and metastasis of hypopharyngeal carcinoma by inhibiting E2F Transcription Factor 1-mediated MNX1 antisense RNA 1.

Authors:  Yi Zheng; Lizhong Su; Jun Tan; Feilin Dong
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

3.  Screening of herbal extracts for TLR2- and TLR4-dependent anti-inflammatory effects.

Authors:  Anne Schink; Jan Neumann; Anna Lena Leifke; Kira Ziegler; Janine Fröhlich-Nowoisky; Christoph Cremer; Eckhard Thines; Bettina Weber; Ulrich Pöschl; Detlef Schuppan; Kurt Lucas
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.